After reporting first quarter losses of 9.9 million dollars, Delmar is poised to hit a bull run, likely due to continued global interest is pursuing medical research.
An old resistance level is reversing to support as sellers struggle to push prices down to previous levels. Ive laid out a long strategy to capitalize on short term growth.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.